Integrase Inhibitors Market Size is valued at USD 27.66 Bn in 2022 and is predicted to reach USD 40.56 Bn by the year 2031 at a 4.5% CAGR during the forecast period for 2023-2031.
Integrase inhibitors are a type of antiretroviral medications that work by inhibiting the viral enzyme integrase, which is responsible for mixing the viral genome into the DNA of the host cell. This is the mechanism of action of integrase inhibitors.
Retroviral reproduction is dependent on integration. Hence, blocking this step can halt the virus's propagation. The high demand for antiretroviral (ARV) medications directly results from many people infected with HIV worldwide. The government is also making efforts to expand HIV testing and treatment options for those who need them. This trend is expected to fuel the need for HIV medications worldwide. Increasing demand for pharmaceuticals to treat HIV infections and an equivalent rise in the number of pharmaceutical companies producing such drugs drives expansion globally and is expected to boost the market expansion in the coming years.
However, the population growth of patients and the high cost of testing during the COVID-19 outbreak may restrain the development of the target market over the predicted time frame. As a result of the global spread of COVID-19, international trade in medical supplies has been disrupted. The pandemic has hampered the expansion of this market because of the uncertainty and interruption in the availability of medications. Furthermore, increasing R&D activities and investments by prominent players are expected to create lucrative growth opportunities in revenue for players operating in the global integrase inhibitors market over the forecast period.
Competitive Landscape:
Some Major Key Players In The Integrase Inhibitors Market:
- Gilead Sciences
- ViiV Healthcare
- Merck & Co., Inc.
- GlaxoSmithKline PLC
- Bristol-Myers Squibb Company
- Johnson & Johnson
- AbbVie Inc.,
- Janssen
- Pharmaceuticals Inc.
- Theratechnologies Inc.
- Shionogi & Co. Ltd.
Market Segmentation
The integrase inhibitors market is segmented based on drug class, indication, distribution channel, and end-user. As per drug class, the market is segmented into first-generation integrase inhibitors, second-generation integrase inhibitors and others. By indication, the market is segmented into HIV infection and other indications. According to the distribution channel, the segmentation includes hospital pharmacies, retail pharmacies, and online pharmacies. the end-user segment comprises hospitals and clinics, research institutes, and others.
As Per The Distribution Channel, The Hospital Pharmacies Segment Is Accounted As A Major Contributor In The Integrase Inhibitors Market
The hospital pharmacies category is expected to hold a major share of the global integrase inhibitors market. It is attributed to an increase in HIV-related hospitalizations. The market is expanding as a result of increasing demand for antiretroviral medications used to treat HIV at hospital pharmacies. The journal Nano Materials published a paper detailing the impressive outcomes of using multiclass combination product therapy to alleviate HIV symptoms. Thus, there is a rise in the adoption of antiretroviral medications prescribed by hospital pharmacists to treat HIV. Additionally, the government expands HIV patients' access to testing and treatment.
The Hospitals And Clinics Segment Witnessed The Rapid Growth
The segment, hospitals and clinics is projected to grow rapidly in the global integrase inhibitors market owing to an increase in the number of people seeking medical attention and the need for antiretroviral medications, especially in countries such as the US, Germany, UK, China, and India.
In The Region, The North American Integrase Inhibitors Market Holds A Significant Revenue Share
The North American integrase inhibitors market is expected to record the maximum market share in terms of revenue in the near future. It can be attributed to the rising number of people living with HIV in the United States. The high number of people who need HIV medication drives up prices.
The existence of major players providing novel HIV medications for treating HIV infection would also contribute to the expansion of the market. Growing demand for HIV treatment medications across industries and the introduction of new drugs and other products also contribute to the expansion of the industry in the region. In addition, Asia Pacific is estimated to grow rapidly in the global integrase inhibitors market because there are more options for care and growing financial support from the business and medical communities.
Integrase Inhibitors Market Report Scope:
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 27.66 Bn |
|
Revenue Forecast In 2031 |
USD 40.56 Bn |
|
Growth Rate CAGR |
CAGR of 4.5% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug Class, By Indication, By Distribution Channel, By End User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Gilead Sciences, ViiV Healthcare, Merck & Co., Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Janssen, Pharmaceuticals Inc., Theratechnologies Inc., Shionogi & Co. Ltd. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
